Skip to main content
. 2018 Feb 23;4(2):141–152. doi: 10.1002/osp4.156

Figure 1.

Figure 1

Participants and group assignments. A total of 242 intent‐to‐treat participants were randomly assigned 1.75:1 to NB + CLI and UC groups. AE, adverse event; LTFU, lost to follow‐up; Other, protocol deviation or withdrawal of consent; N/A, not applicable; CLI, comprehensive lifestyle intervention; NB, sustained release combination of naltrexone and bupropion; Wk 16, evaluation to continue treatment at week 16 visit.